Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

4 of 4 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

N/A
5(100.0%)
5Total
N/A(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05817045Not ApplicableCompleted

Evaluation of the RD-X19 Treatment Device in Individuals With Mild COVID-19

Role: lead

NCT04557826Not ApplicableCompleted

Acute Safety and Acceptability Study of Experimental Device RD19 for Protection From Human Respiratory Disease Pathogens

Role: lead

NCT04966013Not ApplicableCompleted

Evaluation of the RD-X19 Treatment Device in Individuals With Mild to Moderate COVID-19

Role: lead

NCT06113679Not ApplicableTerminated

Pilot Randomized Study of RD-X19 Tx Device in Subjects With PCC (Long Covid) in the Outpatient Setting

Role: lead

NCT04662671Not ApplicableCompleted

Phase I/II Safety, Dose Finding & Antiviral Activity of RD-X19 in Mild/Moderate Outpatient COVID-19

Role: lead

All 5 trials loaded